Bicycle therapeutics to present at the aacr annual meeting 2024

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the american association for cancer research (aacr) annual meeting 2024, taking place in san diego on april 5-10. poster presentation details: title: bicycle toxin conjugates® for the.
BCYC Ratings Summary
BCYC Quant Ranking